RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma

NCT01252251 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Uveal Melanoma

Interventions

DRUG: RAD001 (Everolimus) and Pasireotide (SOM230) LAR

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]